ONO Pharmaceutical Co earnings date
ONO Pharmaceutical Co (ON4) Q1 2026 Earnings Report
DE:ON4 Q1 2026 EPS Results
- Actual EPS
- EUR 0.29
- Consensus EPS
- EUR 0.20
- Beat/Miss
- Beat by +EUR 0.09
- One Year Ago EPS
- EUR 0.21
DE:ON4 Q1 2026 Revenue Results
- Actual Revenue
- EUR 653.41M
- Expected Revenue
- EUR 621.96M
- Beat/Miss
- Beat by +EUR 31.45M
- YoY Revenue Growth
- -8.92%
Earnings Announcement Details
- Quarter
- Q1 2026
- Date
- 07/31/2026
- Time
- Before Open
- Conference Call
- Friday, July 31, 2026
ONO Pharmaceutical Co's next earnings date is estimated for February 1, 2027, based on past reporting schedules.
Q1 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q1 2026 Earnings Slide Deck
Q1 2026 Earnings Call Summary
Mixed but balanced. The quarter delivered the company's highest-ever Q1 revenue (up 8.4% YoY) driven by strong FORXIGA performance and the addition of Deciphera (notably QINLOCK and ROMVIMZA). Strategic pipeline moves (povetacicept acquisition) and regulatory approvals/positive opinions support medium-term growth. However, near-term profitability was weakened by Deciphera operating losses, acquisition-related amortization and increased R&D/SG&A, while OPDIVO faces competitive pressure and slower recovery in lung cancer prescriptions. Management maintained full-year guidance, signaling confidence but with clear execution and timing risks.
guidance reiterated that full-year guidance is unchanged: Q1 revenue rose JPY9.9bn (8.4%) to JPY127.5bn (sales JPY87.8bn, royalties JPY39.8bn), driven by JPY10.1bn of Deciphera sales (QINLOCK JPY8.9bn; ROMVIMZA JPY1.1bn, annualized JPY5bn), while domestic sales fell JPY1.6bn and OPDIVO IV sales dropped JPY2.6bn to JPY29.4bn; FORXIGA grew JPY2.9bn (13%) to JPY25.1bn. Core operating profit fell JPY3.5bn (10.1%) to JPY31.6bn and core profit for the period fell JPY3.9bn (13.7%) to JPY24.8bn (full-IFRS operating profit down JPY8.7bn to JPY22.0bn; profit for the period JPY17.7bn), with R&D up JPY7.4bn and SG&A up JPY6.1bn partly due to Deciphera (Deciphera operating loss JPY4.8bn); reconciling amortization/step-up items totaled about JPY8.9bn. OPDIVO guidance: FY2025 sales target JPY125bn (+JPY4.7bn YoY) with specific new‑patient share goals—gastric 65% now, target 70% by year‑end; esophageal new‑patient share 53% aiming for 60%; lung new‑patient share 17% vs target 30% (PD‑L1‑negative target 50% in FY2025); hepatocellular carcinoma first‑line new‑patient share target 30% by Dec 2026—and ~70,000 existing patients remain untreated for existing indications; timing for new approvals and povetacicept filing remains subject to trial timelines.
- Highest Q1 Revenue on RecordRevenue increased by JPY9.9 billion (8.4% YoY) to JPY127.5 billion, the highest Q1 sales in company history; sales revenue component rose JPY8.4 billion (10.6% YoY) to JPY87.8 billion and royalties/other increased JPY1.4 billion (3.7% YoY) to JPY39.8 billion.
- Strong FORXIGA PerformanceFORXIGA tablets grew JPY2.9 billion (13% YoY) to JPY25.1 billion, showing continued domestic strength across diabetes, chronic heart failure, and chronic kidney disease indications.
- Deciphera Acquisition Driving Overseas GrowthInclusion of Deciphera contributed JPY10.1 billion in sales in Q1. QINLOCK generated JPY8.9 billion in Q1 and is on track with the initial annual forecast of JPY34 billion; ROMVIMZA delivered JPY1.1 billion in Q1 with an expected annual run-rate around JPY5 billion as patient numbers grow.
- Regulatory and Label Expansion ProgressApprovals and positive regulatory actions include OPDIVO + YERVOY approval for first-line hepatocellular carcinoma in Japan (June) and approvals in South Korea and Taiwan; subcutaneous OPDIVO approved in Europe; positive opinion from European Commission for ROMVIMZA (July); multiple pending filings progressing smoothly.
- Pipeline Reinforcement via Strategic LicensingAcquisition of development/commercial rights for povetacicept from Vertex (BAFF/APRIL dual antagonist) — Phase III for IgA nephropathy underway — positioned as potentially best-in-class mechanistically by inhibiting both BAFF and APRIL.
- Domestic Rebound in Gastric Cancer New PrescriptionsOPDIVO new-prescription share in gastric cancer recovered from 57% to 65% in Q1 after competitive pressure; management target of 70% by year-end, supported by long-term follow-up and real-world data promotion.
- Operational Discipline Outside Acquisition EffectsExcluding Deciphera, R&D expenses decreased YoY and SG&A (excluding FORXIGA co-promotion and Deciphera SG&A) remained at prior-year levels, indicating controlled spend on core operations.
- Full-Year Guidance UnchangedCompany maintained its full-year earnings forecasts despite Q1 volatility and acquisition-related items, signaling confidence in hitting previously announced targets.
DE:ON4 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 01, 2027 | 2026 (Q3) | 0.26- | 0.35 | ― | ― |
| Oct 29, 2026 | 2026 (Q2) | 0.240.25 | 0.27 | -7.36% (-0.02) | |
| Jul 31, 2026 | 2026 (Q1) | 0.200.29 | 0.21 | 36.63% (+0.08) | |
| May 08, 2026 | 2025 (Q4) | 0.050.01 | -0.08 | 112.48% (+0.09) | |
| Feb 02, 2026 | 2025 (Q3) | 0.250.35 | 0.18 | 92.96% (+0.17) | |
| Oct 30, 2025 | 2025 (Q2) | 0.230.27 | 0.2 | 33.00% (+0.07) | |
| Aug 01, 2025 | 2025 (Q1) | 0.280.21 | 0.3 | -28.74% (-0.09) | |
| May 08, 2025 | 2024 (Q4) | 0.08-0.08 | 0.27 | -129.41% (-0.34) | |
| Feb 03, 2025 | 2024 (Q3) | 0.240.18 | 0.43 | -57.98% (-0.25) | |
| Oct 31, 2024 | 2024 (Q2) | 0.280.20 | 0.5 | -59.32% (-0.29) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


